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Abstract
Background: This study was conducted to propose the optimal duration of fluoropyrimidine-based adjuvant
chemotherapy consisting of fluoropyrimidine derivatives alone or combined with intravenous platinum for
stage II or III gastric cancer (GC).
Methods: We analyzed retrospectively the data from 2219 patients with histologically confirmed adenocarcinoma in
the stomach, who underwent a curative gastrectomy with lymphadenectomy from 2005 to 2012. Five-year overall
survival (OS) and 3-year relapse-free survival (RFS) were analyzed according to the duration of fluoropyrimidine-based
adjuvant chemotherapy.
Results: Data from 617 patients with stage II or III GC were analyzable; 187 patients (30.3 %) were treated with surgery
alone, while 430 patients (69.7 %) were treated with postoperative adjuvant chemotherapy. The duration of adjuvant
chemotherapy was less than 6 months [group 1] in 147 patients (34.2 %), 6 months to less than 12 months [group 2]
in 94 patients (21.9 %), 1 year to less than 2 years [group 3] in 139 patients (32.3 %), and over 2 years [group 4] in 50
patients (11.6 %). The 5-year OS in groups 1, 2, 3, and 4 was 75.7, 87, 90.3, and 93.4 %, respectively, while 3-year RFS
was 52.5, 58.8, 81.4, and 94.0 %, respectively.
Conclusions: In this retrospective study, we did not demonstrate any significant improvement in OS and RFS by
longer periods of fluoropyrimidine-based adjuvant chemotherapy in stage II or III GCs. Further prospective randomized
studies are needed.
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Background
According to the estimated incidence, mortality and
worldwide prevalence data for 2012 from the Inter-
national Agency for Research on Cancer, gastric cancer
(GC) is the fifth most common malignancy in the
world. With nearly 1 million cases per annum, it is the
third leading cause of cancer-related death in both
sexes worldwide [1]. In addition, GC is the second most
common malignancy in Asia and more than half of
new GCs occur in Eastern Asia [2]. At present, adju-
vant chemotherapy or chemoradiotherapy after surgi-
cal resection of GC is a reasonable option because
high rates of locoregional or distant recurrences have
been reported [3–6].
For the treatment of gastric and gastroesophageal junc-
tion adenocarcinoma, the Intergroup trial 0116 (INT-
0116) in 2001 showed the first high-level evidence for
improved survival from adjuvant therapy in GC [7]. Now-
adays, extensive (D2) lymph-node dissection is recom-
mended because the adequacy of surgical resection is an
important issue. However, only 10 % of patients under-
went D2 dissection, while 36 % had D1 dissection, and
54 % had D0 lymphadenectomy in this trial. The median
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overall survival (OS) in the surgery-only group was
27 months, as compared to 36 months in the adjuvant
chemoradiotherapy group. Since then, postoperative che-
moradiotherapy has become the standard treatment after
a curative resection in the USA. In 2006, the Medical
Research Council Adjuvant Gastric Infusional Chemo-
therapy (MAGIC) trial randomly assigned patients with
resectable stomach, esophagogastric junction, or lower
esophagus cancer to either perioperative chemotherapy
following surgery (250 patients) or surgery alone (253
patients). The primary endpoint was OS. Compared to
the surgery group (23 %), the perioperative chemotherapy
group (36 %) had a higher likelihood of 5-year overall sur-
vival. As the MAGIC trial shows a survival benefit, in
Europe, perioperative chemotherapy with epirubicin, cis-
platin, and 5-fluorouracil (ECF) has become the standard
of care following curative resection [4].
S-1 has been developed mainly in Japan because the
pharmaceutical company producing S-1 is a domestic
Japanese company, and there are sufficient numbers of
patients with gastric cancer in Japan for clinical trials.
Phase II trials of S-1 monotherapy (40 mg/m2, twice a
day, on days 1–28, every 6 weeks) were conducted in
Japan [8]. In 1999, the Japanese government approved
this drug for treating gastric cancer on the basis of the
results of the two domestic phase II trials [9]. S-1 is
a novel oral agent containing tegafur, a prodrug of 5-
fluorouracil (5-FU), and two biochemical modulators
of 5-FU including 5-chloro-2,4-dihydroxypyridine and po-
tassium oxonate. 5-Chloro-2,4-dihydroxypyridine increases
the pharmacological action of 5-FU by inhibiting dihy-
dropyrimidine dehydrogenase. Potassium oxonate, which
localizes to the mucosal cells of the gastrointestinal (GI)
tract after oral administration, reduces GI toxicity by sup-
pressing the activation of 5-FU in the GI tract. In Japan,
the patients with stage II or III GC who underwent gas-
trectomy plus extended (D2) lymph node dissection were
randomly assigned to either the surgery with S-1 adjuvant
therapy group or to the surgery alone group. The primary
endpoint was OS. The 3-year OS rate was 80.1 % in the
S-1 group and 70.1 % in the surgery-only group. The
hazard ratio (HR) for death in the S-1 group compared
to the surgery-only group was 0.68. The OS rate at
5 years was 71.7 % in the S-1 group and 61.1 % in the
surgery-only group. The rate of relapse-free survival
(RFS) at 3 years was 72.2 % in the S-1 group and 59.6 %
in the surgery-only group. The 5-year RFS rate was
65.4 % in the S-1 group and 53.1 % in the surgery-only
group [5]. The CLASSIC study was an open-label,
phase 3, randomized controlled trial undertaken in 37
centers in South Korea, China, and Taiwan. Patients
with stage II, IIIA, and IIIB GC who had undergone
curative D2 gastrectomy were randomly assigned to
either adjuvant chemotherapy with capecitabine plus
oxaliplatin (XELOX) for 6 months or surgery only. The
primary endpoint was 3-year disease-free survival (DFS).
The 3-year DFS was 74 % in the chemotherapy after
surgery group and 59 % in the surgery-only group. The 5-
year OS rate was 78 % in the XELOX group and 69 % in
the surgery alone group. The 5-year DFS rate was 68 % in
the XELOX group and 53 % in the surgery alone group. In
this study, more than half of the patients who received
chemotherapy had peripheral neuropathy, which is a cu-
mulative, dose-related toxic effect associated with oxali-
platin, but grade 3 or 4 events were infrequent [6].
Among the regimens mentioned above, most random-
ized prospective studies have evaluated the effects of
chemotherapy over periods ranging from 6 to 12 months.
Postoperative FU-based oral chemotherapy, such as S-1
for 1 year or capecitabine plus oxaliplatin for 6 months,
is proven as the effective treatments for localized GC
after D2 gastrectomy [5, 6]. However, it is difficult to say
which regimens are better for adjuvant chemotherapy of
GC because they have similar efficacies and different tox-
icities. Although only appropriately designed and powered
randomized clinical trials can address the optimal dur-
ation of adjuvant chemotherapy, because of the relatively
high recurrence rate in GC patients, ethical concerns are
likely to prevent any prospective study of the optimal dur-
ation of adjuvant treatment from being undertaken [10].
Consequently, we wanted to undertake a retrospective
analysis exploring the correlation between adjuvant chemo-
therapy duration and OS or RFS in advance of conducting
a randomized prospective study.
Methods
Patients
The data were collected from 2219 patients with histologi-
cally confirmed adenocarcinoma in the stomach, who
underwent curative gastrectomy with lymphadenectomy
from 2005 to 2012 in Pusan National University Hospital.
The baseline patient characteristics are shown in Table 1.
Study design and treatment
This study is a retrospective study for evaluating the opti-
mal duration of fluoropyrimidine-based adjuvant chemo-
therapy in patients who had initially operable stage II or
III GC. The adjuvant chemotherapy consisted of fluoro-
pyrimidine derivatives (doxifluridine, UFT, S-1, capecit-
abine) alone or combined with platinum (cisplatin or
oxaliplatin). Patients with stage II or III GC were divided
into five stages according to the American Joint Commit-
tee on Cancer staging manual, 7th edition [Fig. 1] [11].
Statistical methods
The primary analysis involved evaluating the association
between the duration of chemotherapy and OS, which
was defined from the time of surgery to death or the last
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follow-up visit. Secondary analysis included 3-year RFS,
which was calculated as the time from surgery to the
time of recurrence. Univariate and multivariate analyses
using a Cox proportional hazard regression model were
carried out, and hazard ratios (HR) were estimated with
95 % confidence interval (95 % CI) limits. Both uni-
variate and multivariate analyses were conducted to
establish the association between prognosis and age,
sex, depth of tumor invasion, lymph node metastasis,
histological type, stage, and the duration of adjuvant
chemotherapy. Survival curves were generated by the
Kaplan–Meier method. A p value of less than 0.05 was
considered significant. All analyses were performed using
SPSS for Windows, version 21.0 (SPSS Inc., Chicago, IL,
USA), and R software, version 3.1.1 (R Foundation for
Statistical Computing).
Results
After patients with any unanalyzable conditions were
excluded, 617 patients with stage II or III GC were en-
rolled. Due to patients’ refusal or postoperative morbid-
ity, 187 patients (30.3 %) were treated with surgery
alone; 430 patients (69.7 %) were treated for diverse
Table 1 Patient and tumor characteristics
Surgery only Adjuvant CT p value
N = 187 N = 430
Sex 0.911
M 127 (67.9) 294 (68.4)
F 60 (32.1) 136 (31.6)
Age (median, years) 0.015
70 (31~96) 66 (29~90)
<65 58 (31.0) 193 (45.0) 0.001
≥65 129 (69.0) 236 (55.0)
Performance status (ECOG) 0.387
0 181 (96.8) 422 (98.1)
1 4 (2.1) 6 (1.4)
2 1 (0.5) 2 (0.5)
3 1 (0.5) 0
Preoperative CEA (ng/mL) 2.2 (0.2~98.8) 2.4 (0.2~169.1) 0.710
Scope of LN dissection 0.004
D1 23 (12.5) 31 (7.2)
D1 + A 1 (0.5) 23 (5.4)
D1 + B 5 (2.7) 23 (5.4)
D2 151 (82.1) 347 (81.1)
D3 4 (2.2) 4 (0.9)
Histology 0.209
Differentiated 88 (47.1) 226 (52.6)
Undifferentiated 99 (52.9) 204 (47.4)
Lymphatic invasion 0.948
No 60 (32.1) 136 (31.6)
Yes 127 (67.9) 293 (68.1)
Unknown 0 1 (0.2)
Depth of tumor invasion
(AJCC 7th)
T stage 0.073
T1a 3 (1.6) 3 (0.7)
T2 26 (13.9) 69 (16.05)
T3 91 (48.7) 165 (38.4)
T4a 58 (31.0) 160 (37.2)
T4b 8 (4.3) 24 (5.6)
N stage <0.001
N0 55 (29.4) 70 (16.28)
N1 48 (25.7) 104 (24.19)
N2 48 (25.7) 108 (25.12)
N3a 25 (13.4) 88 (20.47)
N3b 11 (5.9) 60 (13.95)
Table 1 Patient and tumor characteristics (Continued)
Stage 0.002
IIA 74 (39.6) 102 (23.72)
IIB 35 (18.7) 89 (20.7)
IIIA 27 (14.4) 67 (15.58)
IIIB 24 (12.8) 92 (21.39)
IIIC 27 (14.4) 78 (18.60)
CT chemotherapy
Fig. 1 Kaplan–Meier curves for overall survival according to cancer
stages in patients treated with adjuvant chemotherapy
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durations with various fluoropyrimidine-based adjuvant
chemotherapy regimens. The numbers of male patients
were 294 (68.4 %) and the numbers of female patients
were 136 (31.6 %), and the numbers of patients below
the age of 60, between the ages of 60 and 70, and over
the age of 70 who underwent adjuvant chemotherapy
were 118 (27.5 %), 125 (29.1 %), and 186 (43.4 %),
respectively. The median follow-up duration of OS
was 42.2 months (mean = 41.9, SD = 26.2); the median
follow-up duration of RFS was 14.5 months (mean = 19.4,
SD = 16.7).
The 5-year OS rates for the adjuvant chemotherapy
and surgery-only groups were 86.0 and 81.4 %, respect-
ively. The hazard ratio (HR) for death in the adjuvant
chemotherapy group as compared to the surgery-only
group was 0.891, with a 95 % confidence interval (CI) of
0.54–1.46 (p = 0.647). However, the 3-year RFS rate for
the adjuvant chemotherapy group was 69.3 % compared
to 73.9 % in the surgery-only group. The HR for relapse
in the adjuvant chemotherapy group was 1.226 (95 % CI
0.887–1.695, p = 0.217) [Fig. 2].
The duration of adjuvant chemotherapy was less than
6 months [group 1] in 147 patients (34.2 %), 6 months
to less than 12 months [group 2] in 94 patients (21.9 %),
1 year to less than 2 years [group 3] in 139 patients
(32.3 %), and over 2 years [group 4] in 50 patients (11.6 %)
in Table 2.
Adjuvant chemotherapy regimens for GC in this study
were divided into seven categories depending on the
administration method, which included intravenous (IV),
per oral (PO), or a combination of IV and PO methods.
The most commonly used drugs were doxifluridine,
UFT, and S-1 in order of the decreasing frequency. The
median cycles of the regimens are also listed in Table 3.
The distribution of patients according to durations of
chemotherapy and TNM stages is shown in Table 4.
For subgroup analysis, the 5-year OS and 3-year RFS
rates were analyzed according to the duration of adjuvant
chemotherapy. The reference category of Cox regression
analysis in Fig. 3a, b is no adjuvant treatment or surgery-
only group. Five-year OS rates for groups 1, 2, 3, and 4
were 75.7 % (HR 1.478, 95 % CI 0.833–2.62, p = 0.182),
87 % (HR 1.140, 95 % CI, 0.555–2.344, p = 0.721), 90.3 %
(HR 0.522, 95 % CI 0.254–1.071, p = 0.076), and 93.4 %
(HR 0.437, 95 % CI 0.151–1.264, p = 0.127), respectively.
The 3-year RFS rates for groups 1, 2, 3, and 4 were 52.5 %
(HR 2.099, 95 % CI 1.449–3.040, p = 0.000), 58.8 % (HR
1.584, 95 % CI 1.029–2.438, p = 0.037), 81.4 % (HR 0.737,
95 % CI 0.476–1.142, p = 0.172), and 94.0 % (HR 0.537,
95 % CI 0.272–1.061, p = 0.074), respectively [Fig. 3].
Compared to long-term administration of oral 5-FU
chemotherapy alone, regimens combined with platinum
had a hazardous effect on OS (HR 1.987, 95 % CI 1.127–
3.504, p = 0.018) and RFS (HR 1.694, 95 % CI 1.206–2.38,
Fig. 2 Kaplan–Meier curves for overall survival (a) and relapse-free
survival (b). The rates of overall survival in the adjuvant chemotherapy
and surgery-only groups are 86.0 and 81.4 %, respectively, while the
rates of relapse-free survival are 69.3 and 73.9 %, respectively. The hazard
ratio for death in the adjuvant chemotherapy group as compared to
the surgery-only group is 0.891 (95 % confidence interval 0.54–1.46,
p= 0.647). The hazard ratio for relapse in the adjuvant chemotherapy
group is 1.226 (95 % confidence interval 0.887–1.695, p = 0.217). p values
were calculated using the stratified log-rank test
Table 2 The proportions according to the lengths of
chemotherapy
Durations of chemotherapy n (%)
<6 M 147 (34.2 %)
6~12 M 94 (21.9 %)
12~24 M 139 (32.3 %)
>24 M 50 (11.6 %)
n number of patients, M months
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p = 0.002) [Fig. 4]. p values were calculated using the
stratified log-rank test.
Multivariate analyses of OS revealed the prognostic
significance of the depth of tumor invasion, lymph node
metastasis, and 12- to 24-month duration of adjuvant
chemotherapy in Table 5. Multivariate analyses of RFS
also showed the prognostic significance of the depth of
tumor invasion, lymph node metastasis, histological
type, and periods of adjuvant chemotherapy over 12 and
24 months in Table 6.
Discussion
In order to improve OS or RFS with adjuvant chemo-
therapy, both duration and cumulative dose intensity of
adjuvant treatment are as important as the regimen. As
the optimal length of time for adjuvant chemotherapy
has not been established, if adjuvant chemotherapy does
not adversely affect patients, continuation of chemother-
apy over the planned period should be considered. There-
fore, in Japan, a retrospective study was conducted to
evaluate the effectiveness of oral anti-cancer drugs (for
2 years) as postoperative adjuvant chemotherapy in GC
patients [12]. Authors divided the 20 years chronologically
into the UFT (5-FU analog, tegafur combined with uracil
in a ratio of 1:4, Taiho Pharmaceutical Co. Ltd., Tokyo,
Japan) term (1989–2003) and the S-1 term (2004–2008).
The patients from each term were then divided into three
groups according to the length of drug administration,
namely, the surgery-alone group, the 1-year group, and
the 2-year group. The survival time of the 2-year group
Table 3 The names and median cycles of regimens used as
adjuvant chemotherapy
Regimens Number Percent Cycles
Doxifluridine (D1–28) q 4w 205 47.7 19.9
UFT (D1–28) q 4w 57 13.3 11.9
S-1 (D1–28) q 6w 51 11.9 5.0
Capecitabine (D1–14) + cisplatin (D1) q 3w 48 11.2 6.8
5-FU (D1–5) + cisplatin (D1) q 3w 44 10.2 5.7
S-1 (D1–14) + cisplatin (D1) 18 4.2 5.7
Oxaliplatin (D1) + leucovorin (D1–2) + 5-FU
(D1–2) q 2w
7 1.6 12.6
n number of patients, q every, w weeks, D day
Table 4 The distribution of patients according to durations of
chemotherapy and TNM stages
Stage (TNM) Durations of chemotherapy
<6 M 6~12 M 12~24 M >24 M
IIA 25 (17.0 %) 13 (13.8 %) 46 (33.0 %) 18 (36.0 %)
IIB 21 (14.3 %) 21 (22.3 %) 34 (24.4 %) 13 (26.0 %)
IIIA 24 (16.3 %) 14 (14.9 %) 22 (15.8 %) 7 (14.0 %)
IIIB 39 (26.5 %) 21 (22.3 %) 23 (16.5 %) 9 (18.0 %)
IIIC 38 (25.9 %) 25 (26.6 %) 14 (10.0 %) 3 (6.0 %)
Numbers in parenthesis represent the row percentages
M months
Fig. 3 Kaplan–Meier curves for overall survival (a) and relapse-free
survival (b) according to adjuvant chemotherapy durations in patients
with gastric cancer. The duration of adjuvant chemotherapy was less
than 6 months [group 1] in 147 patients (34.2 %), from 6 months to
less than 12 months [group 2] in 94 patients (21.9 %), from 1 year to
less than 2 years in [group 3] 139 patients (32.3 %), and over 2 years
[group 4] in 50 patients (11.6 %). The reference category of Cox
regression analysis in Fig. 3a, b is no adjuvant treatment or
surgery-only group. Five-year OS rates for groups 1, 2, 3, and 4
were 75.7 % (HR 1.478, 95 % CI 0.833–2.62, p = 0.182), 87 % (HR
1.140, 95 % CI, 0.555–2.344, p = 0.721), 90.3 % (HR 0.522, 95 % CI
0.254–1.071, p = 0.076), and 93.4 % (HR 0.437, 95 % CI 0.151–1.264, p =
0.127), respectively. The 3-year RFS rates for groups 1, 2, 3, and 4 were
52.5 % (HR 2.099, 95 % CI 1.449–3.040, p = 0.000), 58.8 % (HR 1.584,
95 % CI 1.029–2.438, p = 0.037), 81.4 % (HR 0.737, 95 % CI 0.476–1.142,
p = 0.172), and 94.0 % (HR 0.537, 95 % CI 0.272–1.061, p = 0.074),
respectively [Fig. 3]. p values were calculated with the use of the
stratified log-rank test
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was better than that of the surgery-alone group, not only
in the UFT term, but also in the S-1 (p = 0.0224). Longer
RFS was evident in the S-1 term, especially for the 2-year
group (p = 0.0110), and a multivariate analysis showed that
both the stage of the cancer and 2 years of postoperative
adjuvant chemotherapy were independent factors predict-
ive of prolonged survival. Not only in the retrospective
study but also in the randomized trial of S-1 for gastric
cancer (ACTS-GC), the duration of adjuvant chemother-
apy was proportional to the overall survival. Among the
517 patients in the safety population who received S-1,
the persistence rate of S-1 treatment for 12 months was
just 65.8 %. Besides, the dose was decreased in half of the
patients who received treatment for 12 months [5]. The
reasons for treatment withdrawal were patient refusal or
investigator decisions due to adverse events or complica-
tions, metastasis, relapse, or presence of another cancer
[5, 13]. For another examples, the recurrence of GIST is
common in the initial years following discontinuation of
adjuvant imatinib treatment. So more than 12 months
could be reasonable for adjuvant treatment of patients
with a highly estimated risk of GIST recurrence after sur-
gery [14]. Joensuu and colleagues [15] investigated and
concluded that 3 years of adjuvant imatinib administration
improved RFS and OS in GIST patients with a high risk
of recurrence compared to 1 year of imatinib. When it
comes to women with estrogen receptor-positive breast
cancer, continuing tamoxifen for 10 years rather than
stopping at 5 years produces a further reduction in re-
currence and mortality, particularly after 10 years [16].
However, this opinion is likely to evoke strong oppos-
ition from other studies. Colleoni M. et al. reported that
Fig. 4 Kaplan–Meier curves for overall survival (a) and relapse-free
survival (b) in the oral 5-fluorouracil alone group (n = 313) versus the
platinum-based group (n = 117). The oral 5-fluorouracil-alone group
has better overall survival compared to the platinum-based group
(hazard ratio 1.987, 95 % confidence interval 1.127–3.504, p = 0.018)
and relapse-free survival (hazard ratio 1.694, 95 % confidence interval
1.206–2.38, p = 0.002). p values were calculated using the stratified
log-rank test
Table 5 Univariate and multivariate analyses of prognostic









<65 vs. >65 years .154 .094 0.663 0.410–1.073
Sex
Male vs. female .596 .302 0.757 0.447–1.284
Depth of tumor invasion
t1, 2 vs. t3, 4 <.001 .014 5.176 1.390–19.269
Lymph node metastasis




.348 .703 0.547 0.362–1.985
Lauren classification
Diffuse vs. intestinal .170 .556 1.271 0.572–2.825
Stage
II vs. III <.001 .851 1.142 0.286–4.559
Period of adjuvant chemotherapy
<6 months .182 .374 0.877 0.476–1.616
6~12 months .721 .267 0.655 0.310–1.383
12~24 months .076 .005 0.347 0.167–0.726
>24 months .127 .061 0.358 0.123–1.047
CI confidence interval, OS overall survival
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3 cycles of cyclophosphamide/methotrexate/fluorouracil
(CMF) would be sufficient for women aged under 40
with hormone receptor positive, potentially endocrine
responsive node-positive disease if CMF were followed
by effective endocrine therapy. For women of any age
with tumors that do not express any steroid hormone
receptors (ER-absent) (a relatively small subgroup of
patients), the issue of adjuvant chemotherapy duration
requires further study, but this results do not suggest
that adjuvant CMF can safely be reduced to 3 cycles in
these women [17]. With regard to colorectal cancer, Des
Guetz G. and his colleagues performed a meta-analysis
of all RCTs comparing two durations of 5-FU-based adju-
vant treatment, 6 months versus 9 to 12 months. Shorter
duration of chemotherapy (3–6 months) compared with
longer duration (9–12 months) was not associated to
poorer RFS (RR = 0.96, 95 % CI 0.90–1.02) and OS (RR =
0.96, 95 % CI 0.91–1.02). This meta-analysis confirmed
that adjuvant chemotherapy of CRC should not last for
more than 6 months [18].
Besides heterogeneous regimens and inadequate med-
ical records, this study has so many difficulties in being
comprehended because the data derived from changes in
chemotherapy schedule or fluoropyrimidine dosage were
not directly connected to compliance in our patients.
The reasons why patients were treated with no chemo-
therapy or with 6–12 to 24 months of chemotherapy
and why patients were treated with single agent or com-
bination were presumed to be are because of physician’s
choice or intolerance to chemotherapy in patients with
adverse reactions. Toxicity profiles were not recorded
schematically in most patients. However, unbearable
adverse events like nausea, vomiting, and peripheral
neuropathy were more common in platinum-combined
regimens, which were not administered for more than
6 months traditionally. No patient received 1 or 2 years
of platinum-based regimen was found in this study. On
the other hand, most of single oral FU-based chemo-
therapy regimens were administered for more than
6 months, as pointed out in the introduction, long-term
oral administration of fluoropyrimidines such as doxi-
fluridine or tegafur was commonly used as adjuvant
chemotherapy for gastric cancer because the optimal
period or optimal total doses of fluoropyrimidines have
been rarely studied.
In the results, we found that the 3-year RFS rate is
lower in the adjuvant chemotherapy group than in the
surgery-only group. Perhaps, it seems like main reason
that relatively more patients with high nodal stage were
included in the adjuvant chemotherapy group than in
the surgery only group as shown in Table 1.
There are still unresolved issues. Firstly, adjuvant chemo-
therapy does not prolong OS [Fig. 2a] and RFS [Fig. 2b]
over surgery alone. Secondly, OS and RFS is significantly
lower in the <6, 6-12 months of adjuvant chemotherapy
group than in surgery only group [Fig. 3a-b]. The most
likely explanation of this phenomenon is that stage III pa-
tients with poor prognosis are located dominantly in the
left lower quadrant area of Table 3. Thirdly, 12-24 months
of adjuvant chemotherapy significantly prolong OS and
RFS at multivariate analysis, not at univariate analysis.
Unfortunately, we cannot give explicit answers to these
complex statistical issues except that retrospective data ana-
lysis are susceptible to bias in data selection and it may
show associations among variables, but rarely establishes
causal relationships [19].
Conclusions
By this retrospective analysis, the authors did not verify
that the prolonged administration of oral fluoropyrimidine
derivatives as postoperative adjuvant chemotherapy could
lead to a favorable outcome for stage II and III GC patients.
Therefore, we propose further prospective randomized
studies to determine the appropriate fluoropyrimidine-
based regimens and optimal duration of adjuvant chemo-
therapy for higher OS and RFS in GC patients.
Table 6 Univariate and multivariate analyses of prognostic









<65 vs. >65 years .667 .485 1.110 0.829–1.485
Sex
Male vs. female .831 .820 0.965 0.708–1.315
Depth of tumor invasion
t1, 2 vs. t3, 4 <.001 .005 2.382 1.304–4.353
Lymph node metastasis




.904 .015 0.516 0.303–0.881
Lauren classification
Diffuse vs. intestinal .050 .012 1.936 1.158–3.237
Stage
II vs. III <.001 .115 1.706 0.877–3.319
Period of adjuvant chemotherapy
< 6 months <.001 .049 1.481 1.001–2.192
6~12 months .037 .487 1.171 0.750–1.829
12~24 months .172 .022 0.593 0.379–0.926
>24 months .074 .018 0.438 0.221–0.870
CI confidence interval, RFS relapse-free survival
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